Domů › Mnohočetný myelom › Wisconsin › Milwaukee
Klinické studie Mnohočetný myelom v Milwaukee, WI
21 studií pro Mnohočetný myelom hledá účastníky v lokalitách v Milwaukee a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Probíhá náborFáze 3
- Research Site, Milwaukee
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Probíhá náborFáze 1/2
- Medical College of Wisconsin, Milwaukee
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 3
- Medical College Of Wisconsin, Milwaukee
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Probíhá náborFáze 4
- Froedtert Memorial, Milwaukee
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1/2
- The Medical College of Wisconsin, Milwaukee
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Probíhá náborFáze 2
- Aurora Cancer Care Milwaukee, Milwaukee
- Aurora St. Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- a dalších 4
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Probíhá náborFáze 3
- Medical College of Wisconsin, Milwaukee
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Probíhá náborFáze 3
- Medical College of Wisconsin, Milwaukee
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 1/2
- Research Site, Milwaukee
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Probíhá náborFáze 3
- Aurora Cancer Care-Milwaukee, Milwaukee
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee, Milwaukee
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus, Milwaukee
- a dalších 13
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Probíhá náborFáze 1/2
- Research Site, Milwaukee
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
Probíhá náborFáze 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 2
- MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
Probíhá nábor
- Medical College of Wisconsin, Milwaukee
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Probíhá náborFáze 3
- Froedtert Memorial Lutheran Hospital, Milwaukee
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Probíhá náborFáze 2
- Medical College of Wisconsin, Milwaukee
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Probíhá náborFáze 1
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Probíhá náborFáze 2
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Probíhá náborObservační studie
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 1
- Froedtert and the Medical College of Wisconsin, Milwaukee
Studie Mnohočetný myelom v jiných městech
- New York City, NY60 studií
- Boston, MA42 studií
- Atlanta, GA41 studií
- Houston, TX38 studií
- Durham, NC37 studií
- Nashville, TN32 studií
- Denver, CO27 studií
- Rochester, MN24 studií
- St. Louis, MO24 studií
- Columbus, OH24 studií
- Baldwin Park, CA23 studií
- Chicago, IL22 studií
Další studie v Milwaukee
- Rakovina prsu23 studií
- Nemalobuněčný plicní karcinom22 studií
- Rakovina (všechny typy)22 studií
- Rakovina plic21 studií
- Rakovina prostaty20 studií
- Folikulární lymfom19 studií
- Rakovina slinivky břišní18 studií
- Non-Hodgkinův lymfom18 studií
- Rakovina vaječníků17 studií
- Akutní myeloidní leukemie17 studií
- Burkittův lymfom16 studií
- Srdeční selhání16 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.